SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the focal point, with traders watching guidance, subscriber engagement, advertising growth, and content strategy amid leadership changes and layoffs. Bearish concerns about competition, content quality, and slowing growth contrast with bullish hopes that low expectations and ad expansion could support a positive reaction.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is drawing attention as traders position around the full Phase 3 melanoma cancer-vaccine data presentation at ESMO, following previously reported positive topline results. Bulls see the readout as validation of the oncology pipeline, while skeptics warn that expectations and valuation are elevated and debate whether the event could prompt profit-taking.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound is drawing attention, with traders attributing the move to possible short covering and technical buying rather than a confirmed new company announcement. The broader debate centers on upcoming DM1 and FSHD siRNA data: Novartis/Aviditys DM1 trial failure raised concerns about whether target knockdown can translate into patient benefit, while some traders argue Sareptas distinct delivery approach and the loss of a competitor could be favorable.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are falling amid concern over plans to list its Monee financial-services arm and launch Sea Cloud, which traders worry could add spending and strategic uncertainty. The community is split between viewing a Monee separation as a potential value unlock and fearing it could weaken the remaining business, while some see the selloff as an overreaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings beat and a new buyback authorization, as traders focus on narrowed full-year profit guidance with an unchanged midpoint and weaker vehicle sales. Some view the drop as overdone given the stronger cash-flow outlook and buyback, while others see the outlook as too cautious to offset the earnings-day disappointment.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces earnings beat and raised outlook drew attention as shares sold off despite strong demand, with traders frustrated by the reaction. The debate centers on whether higher costs, weaker cash generation and an insurance loss outweigh the stronger orders and guidance.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel results in progressive MS, alongside new BRIUMVI data. Traders are hopeful azer-cel could add a growth opportunity beyond BRIUMVI, while recognizing the early readouts efficacy is uncertain; continued BRIUMVI sales growth is the more established part of the story.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers push to a fresh 52-week high is drawing attention, with traders celebrating a long-awaited recovery and debating whether the breakout can hold or will meet resistance. Some point to defensive-sector demand and pipeline progress, while others say the move needs a clearer company-specific catalyst.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention to the drugs potential and analyst optimism. Traders are debating whether the placebo-adjusted benefit is modest and whether agitation concerns and higher discontinuations could limit the upside, with some viewing the move as vulnerable to a fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp is driving a sharp rally, with traders viewing the cash proceeds as a balance-sheet and strategic boost. Others question the deal because the divested unit contributes revenue, raising concerns about debt and the outlook for the remaining business; some traders are also taking profits after the surge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure  

Equity

Growth prospects, business challenges, legal changes, and rising competition from SpaceX shaped Wall Street activity this week.

Array Technologies, Inc. (ARRY) Suffers a Larger Drop Than the General Market: Key Insights

Array Technologies, Inc. (ARRY) concluded the recent trading session at $3.38, signifying a -5.32% move from its prior day's close.

Is NXT Worth Buying as Growth Broadens but Execution Risks Build?

Nextpower's expanding solar platform and $5.5 billion-plus backlog fuel growth prospects, but rising costs, U.S. concentration and valuation pose risks.

Implied Volatility Surging for Array Technologies Stock Options

Investors need to pay close attention to ARRY stock based on the movements in the options market lately. 

Array Technologies, Inc. (ARRY) Stock Sinks As Market Gains: Here's Why

Array Technologies, Inc. (ARRY) reached $3.9 at the closing of the latest trading day, reflecting a -4.41% change compared to its last close.

Array Technologies, Inc. (ARRY) Dips More Than Broader Market: What You Should Know

Array Technologies, Inc. (ARRY) closed at $3.83 in the latest trading session, marking a -4.96% move from the prior day.

Array Technologies, Inc. (ARRY) Stock Moves -2.70%: What You Should Know

In the closing of the recent trading day, Array Technologies, Inc. (ARRY) stood at $3.96, denoting a -2.7% move from the preceding trading day.

LEN, ARRY Stocks Hit New Lows As Price Target Cuts Pile Up — What’s Driving The Selloff?

UBS downgraded Array Technologies to ‘Neutral’ from ‘Buy,’ citing concerns about future cash flows, while weak margins led Wall Street to reduce the target on Lennar’s stock.

Here's Why Array Technologies, Inc. (ARRY) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Array Technologies, Inc. (ARRY) Dipped More Than Broader Market Today

In the latest trading session, Array Technologies, Inc. (ARRY) closed at $4.2, marking a -4.11% move from the previous day.

Array Technologies, Inc. manufactures ground-mounting systems used in solar energy projects. The company sells its products to engineering, procurement and construction firms that build solar energy projects and to large solar developers, independent power producers and utilities, master supply agreements or multi-year procurement contracts. It has offices in Europe, Central America, and Australia. The company's products include DuraTrack and SmarTrack. Array Technologies was founded by Ronald P. Corio in 1989 and is headquartered in Albuquerque, NM.

Array Technologies Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Crocs stock rose 8.5% this week as Barclays upgraded it to ‘Overweight’ from ‘Equal Weight’.</li><li>Liquidia stock surged 27% this week, its strongest since May, after settling six lawsuits with United Therapeutics.&nbsp;</li><li>Albertsons faced downgrades after its Q2 results, as concerns grew over operational hurdles.&nbsp;</li></ul><p>Wall Street analysts warmed to Crocs Inc. (CROX) and Liquidia Corp. (LQDA) on growth potential and easing legal risks, while Albertsons Companies (ACI) faced downgrades from three firms. Meanwhile, SpaceX’s growing ambitions rattled sentiment around AT&amp;T (T) and AST SpaceMobile (ASTS), triggering concerns over telecom competition and satellite launch plans.&nbsp;</p><h2 class="st-heading-2">Product Momentum Supports Crocs Upgrade</h2><p><a href="https://stocktwits.com/symbol/CROX">Crocs stock</a> gained 8.5% this week as the company received an upgrade to ‘Overweight’ from ‘Equal Weight’ at Barclays, which increased its price target to $139 from $118. The firm sees a clearer route to expansion over the coming years.</p><p>Barclays believes improving conditions across the business could help Crocs move past a period of uneven performance. Although its North American operations continue to face short-term challenges, investments in new products, additional categories, and brand development appear to be supporting demand. International operations are already generating sales growth.</p><p>Last month, Crocs CFO Patraic Reagan said footwear demand naturally rises and falls every few years, but Crocs is reducing its reliance on classic clogs by expanding into sandals, ballet flats, recovery shoes and other styles. Its sandal business generates nearly $500 million annually. The company is also expanding HEYDUDE into products for activities like boating, fishing and work.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261016_043744873_5d87402f2b.png" alt="koyfin_20261016_043744873.png" width="2400" height="1240"></figure><h2 class="st-heading-2">Legal Settlement Lifts Liquidia Outlook</h2><p><a href="https://stocktwits.com/symbol/LQDA">Liquidia stock</a> has climbed 27% and is on track for its best week since May after it won upgrades from LifeSci Capital and BTIG after reaching an agreement with United Therapeutics Corp. (UTHR) that resolves six outstanding lawsuits between the companies.</p><p>LifeSci Capital analyst Gaurav Maini raised Liquidia to ‘Outperform’ from ‘Market Perform’ and established a $59 price target. The firm believes the agreement removes a major source of uncertainty, allowing Yutrepia to remain available for pulmonary arterial hypertension while removing its use for pulmonary hypertension associated with interstitial lung disease from the label. The settlement could also make Liquidia more attractive to potential strategic partners or buyers.</p><p>Separately, BTIG moved to ‘Buy’ from ‘Neutral’ and set a $70 target. The firm viewed the settlement terms more positively than it had expected before the announcement.</p><h2 class="st-heading-2">Array Technologies Draws Contrarian Interest</h2><p><a href="https://stocktwits.com/symbol/ARRY">Array Technologies stock</a> was upgraded to ‘Outperform’ from ‘Neutral’ by Mizuho, even as the firm cut its price target to $5 from $7. The stock has dropped 61% this year, but the analyst sees room for gains compared with the risk of further losses.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261016_044341010_b622791540.png" alt="koyfin_20261016_044341010.png" width="2400" height="1240"></figure><p>Mizuho believes investors are too worried about weaker demand and the company’s need for cash. The firm expects business to improve in 2027, supported by existing orders and acquisitions that could help cut costs and improve efficiency. It also expects sales and profit margins to outperform market forecasts.&nbsp;</p><h2 class="st-heading-2">Albertsons Faces Multiple Analyst Downgrades</h2><p><a href="https://stocktwits.com/symbol/ACI">Albertsons Companies stock</a> faced three analyst downgrades this week after its fiscal second-quarter results, as concerns grew over its business plan and financial outlook.</p><p>JPMorgan lowered its rating to ‘Neutral’ from ‘Overweight’ but kept its $14 price target unchanged. Although Albertsons shares are cheaper than those of many U.S. grocery rivals, the firm believes ongoing business challenges and weaker-than-expected cost-cutting efforts may explain the lower valuation.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261016_044948856_fe781ba6d5.png" alt="koyfin_20261016_044948856.png" width="2400" height="1240"></figure><p>Goldman Sachs and Bank of America downgraded Albertsons and cut their price targets, citing uncertainty about the company’s growth plans and a suspended 2026 forecast. The analysts expect the stock to remain in a narrow range until management provides more details on its growth plans after completing a business review by spring 2027.</p><h2 class="st-heading-2">SpaceX Competition Clouds AT&amp;T,&nbsp; AST SpaceMobile Prospects</h2><p><a href="https://stocktwits.com/symbol/T">AT&amp;T stock</a> was downgraded to ‘Market Perform’ from ‘Outperform’ by Bernstein, which lowered its price target to $24 from $25. The analyst sees growing competition from SpaceX across broadband and wireless services as an additional challenge for established telecom providers.</p><p>Bernstein also cited recent pricing decisions by incumbent carriers and the possibility of seasonal weakness in the fourth quarter.&nbsp;<a href="https://stocktwits.com/symbol/ASTS">AST SpaceMobile stock</a> was downgraded to ‘Neutral’ from ‘Overweight’ at Piper Sandler, which cut its price target to $54 from $98. The firm has less confidence in the company's planned satellite deployment pace in 2026 and 2027.</p><p>SpaceX’s $8 billion purchase of mobile spectrum last week has raised concerns about competition in satellite-based phone services. Piper warned that SpaceX could limit rocket launch access for partners like AST SpaceMobile, delaying the company’s satellite deployment plans.&nbsp;</p><p>So far this year, CROX and LQDA have gained 0.8% and 45%, respectively, while ARRY, ACI, T and ASTS stocks have declined between 5% and 61%.&nbsp;</p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aa-stock-rises-overnight-alcoa-ceo-bets-on-massena-east-for-cash-pump-as-alumina-market-tightens/cZx0w5uRBs2">AA Stock Rises Overnight: Alcoa CEO Bets On Massena East For Cash Pump As Alumina Market Tightens</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

A Crocs logo sign is seen in New York City, United States.

Wall Street analysts warmed to Crocs Inc. (CROX) and Liquidia Corp. (LQDA) on growth potential and easing legal risks, while Albertsons Companies (ACI) faced downgrades from three firms. Meanwhile, SpaceX’s growing ambitions rattled sentiment around AT&T 

Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure

Albertsons Companies Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

Crocs Inc

Liquidia Corp

SpaceX

AT&T Inc

United Therapeutics Corp

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$3.39
Prev Close	$3.26
Open	$3.22
Dividend Yield	0.00%
50-Day Moving Average	$4.30
Beta	1.55
Avg. Volume	6.44M
PE Ratio	-3.36

52-Week High	$12.23
52-Week Low	$3.20
Market Capitalization	$502.07M
EPS (Annual)	-$0.7345
Price to Book	-2.48
Revenue Per Employee	$1.07M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARRY Fundamentals